Vision (#731)
Laufzeit: 01.01.2019 - 31.12.2040
Kurzfassung
A Phase II single-arm trial to investigate Tepotinib in advanced (stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations (VISION)
Laufzeit: 01.01.2019 - 31.12.2040
A Phase II single-arm trial to investigate Tepotinib in advanced (stage IIIB/IV) non-small cell lung cancer with MET exon 14 (METex14) skipping alterations (VISION)
